Clinical Trial

SHR2554 Clinical Study of Chidamide in the Treatment of T-cell Lymphoma

Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated January 8, 2026 (before its estimated May 2026 completion). Its status may not reflect the trial's current state.
Summary
This study was designed to compare the efficacy and safety of SHR2554 with Chidamide in patients with relapsed/refractory PTCL.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2023-11-05; most recent amendment 2026-01-06.
Status change: Not Yet Recruiting → Recruiting 2024-01-30
Trial Details
NCT Number NCT06122389
Lead Sponsor Jiangsu HengRui Medicine Co., Ltd.
Conditions Relapsed/Refractory PTCLT With at Least One Line of Prior Systemic Therapy
Enrollment 130 participants
Start Date 2024-02-05
Primary Completion 2026-05 (estimated)
Study Completion 2026-07 (estimated)
Updated on ClinicalTrials.gov 2026-01-08